OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 6 of 33

7 Concomitant Pharmacotherapy Variable effects on body weight: • Some tricyclic antidepressants (secondary amines)   ▶ Desipramine   ▶ Nortriptyline   ▶ Protriptyline • Some selective serotonin reuptake inhibitors   ▶ Escitalopram   ▶ Sertraline • Some serotonin and norepinephrine re-uptake inhibitors   ▶ Desvenlafaxine   ▶ Duloxetine • Some irreversible MAOIs (i.e., tranylcypromine) • Some other serotonergic agents   ▶ Vortioxetine Mood Stabilizers May increase body weight: • Gabapentin • Divalproex • Lithium • Valproate • Vigabatrin • Cariprazine • Carbamazepine Variable/neutral effects on body weight: • Lamotrigine (sometimes reported to decrease body weight) • Oxcarbazepine Migraine Medications May increase body weight: • Amitriptyline • Gabapentin • Paroxetine • Valproic acid • Some beta-blockers May decrease body weight: • Topiramate • Zonisamide Neutral effects on body weight: • Non-steroidal anti- inflammatory drugs (NSAIDs) • Triptans (e.g., sumatriptan, rizatriptan, zolmitriptan) • 5-HT 1F receptor agonist (i.e., lasmiditan) • Dihydroergotamine • Calcitonin gene-related peptide receptor (CGRP) receptor antagonists (e.g., ubrogepant, rimegepant, galcanezumab, atogepant) (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024